Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
156,709,131
-
Share change
-
+928,675
-
Total reported value
-
$6,624,104,038
-
Put/Call ratio
-
104%
-
Price per share
-
$42.27
-
Number of holders
-
206
-
Value change
-
+$38,698,690
-
Number of buys
-
125
-
Number of sells
-
76
Institutional Holders of CEREVEL THERAPEUTICS HLDNG I - COM (CERE) as of Q1 2024
As of 31 Mar 2024,
CEREVEL THERAPEUTICS HLDNG I - COM (CERE) was held by
206 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
156,709,131 shares.
The largest 10 holders included
Bain Capital Investors LLC, PERCEPTIVE ADVISORS LLC, Avoro Capital Advisors LLC, VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, FIL Ltd, OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC), ALPINE ASSOCIATES MANAGEMENT INC., and Paradigm Biocapital Advisors LP.
This page lists
206
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.